IDXX stock icon

Idexx Laboratories
IDXX

$470.41
1.03%

Market Cap: 38.8B

 

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Employees: 11,000

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1% less repeat investments, than reductions

Existing positions increased: 394 | Existing positions reduced: 397

5% less capital invested

Capital invested by funds: $40.4B [Q4 2023] → $38.5B (-$1.91B) [Q1 2024]

2% less funds holding

Funds holding: 1,124 [Q4 2023] → 1,107 (-17) [Q1 2024]

1.74% less ownership

Funds ownership: 87.81% [Q4 2023] → 86.07% (-1.74%) [Q1 2024]

16% less first-time investments, than exits

New positions opened: 92 | Existing positions closed: 109

25% less funds holding in top 10

Funds holding in top 10: 28 [Q4 2023] → 21 (-7) [Q1 2024]

53% less call options, than puts

Call options by funds: $104M | Put options by funds: $223M

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$510
8%
upside
Avg. target
$581
24%
upside
High target
$655
39%
upside

6 analyst ratings

positive
67%
neutral
33%
negative
0%
Stifel
Jonathan Block
8%upside
$510
Hold
Maintained
24 Jun 2024
Morgan Stanley
Erin Wright
27%upside
$596
Overweight
Maintained
14 May 2024
Barclays
Balaji Prasad
21%upside
$570
Overweight
Maintained
2 May 2024
JP Morgan
Chris Schott
34%upside
$630
Overweight
Maintained
6 Feb 2024
Barclays
Balaji Prasad
39%upside
$655
Overweight
Maintained
6 Feb 2024

Financial journalist opinion

Based on 3 articles about IDXX published over the past 30 days